
IN THE SPECIFICATION

RECEIVED  
AUG 27 2003  
TECH CENTER 1600/2900

Please amend the specification as follows:

Please amend the paragraph at page 3, line 15 to page 4, line 4 as follows:


The present invention provides indole compounds of formula (I):



wherein  $R^1$  is lower alkyl, lower alkenyl, (hydroxy)lower alkyl, lower alkynyl, phenyl, benzyl or 2-thienyl,  $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  are the same or different and are each hydrogen or lower alkyl; each  $R^6$  is individually hydrogen, lower alkyl, hydroxy, (hydroxy)lower alkyl, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro or halo,  $n$  is 1-3,  $R^7$  is hydrogen, lower alkyl or lower alkenyl,  $X$  is oxy and thio,  $Y$  is carbonyl,  $(CH_2)_{1-3}$ ,  $(CH_2)_{1-3}C(O)$ , or  $(CH_2)_{1-3}SO_2$  and  $Z$  is  $(\omega-(4\text{-pyridyl}))(C_2-C_4 \text{ alkoxy})$ ,  $(\omega-(R^8)(R^9) \text{ amino})(C_2-C_4 \text{ alkoxy})$ , wherein  $R^8$  and  $R^9$  are each H,  $(C_1-C_3)$ alkyl or together with N are a 5- or 6-membered heterocyclic ring comprising 1-3 N( $R^8$ ), S or nonperoxide O; an amino acid ester of  $(\omega-(HO)(C_2-C_4))$ alkoxy,  $N(R^8)CH(R^8)CO_2H$ ,  $OCH_2CH_2N(CH_3)_3^+$ , or 1'-D-glucuronyloxy; or  $Y-Z$  is  $(CH_2)_{1-3}R^{10}$  wherein  $R^{10}$  is OH,  $(C_2-C_4)$ acyloxy,  $SO_3H$ ,  $PO_4H_2$ ,  $N(NO)(OH)$ ,  $SO_2NH_2$ ,  $PO(OH)NH_2$ ,  $[OCH_2CH_2N(CH_3)_3^+]$  or tetrazolyl; or a pharmaceutically acceptable salt thereof.

Please amend the paragraph at page 8, lines 5 to 23, as follows:

Indole compounds of the present inventions include compounds of formula (I):



wherein  $R^1$  is selected from the group consisting of lower alkyl, lower alkenyl, (hydroxy)lower alkyl, lower alkynyl, phenyl, benzyl and 2-thienyl,  $R^2$ ,  $R^3$ ,  $R^4$  and  $R^5$  are the same or different and are each selected from the group consisting of hydrogen and lower alkyl, each  $R^6$  is individually selected from the group consisting of hydrogen, lower alkyl, hydroxy, (hydroxy)lower alkyl, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro and halo,  $n$  is 1-3,  $R^7$  is selected from the group consisting of hydrogen, lower alkyl and lower alkenyl,  $X$  is selected from the group consisting of oxy and thio,  $Y$  is selected from the group consisting of carbonyl  $(CH_2)_{1-3}$ ,  $(CH_2)_{1-3}SO_2$  or  $(CH_2)_{1-3}C(O)$ , and  $Z$  is selected from the group consisting of hydroxy, lower alkoxy optionally substituted with OH, 4-pyridyl, amino, lower alkylamino, di(lower alkyl)amino,  $[[\oplus]] OCH_2CH_2N(CH_3)_3^+$ , N-morpholino; amino, lower alkylamino,  $[(\text{carboxy})(\text{lower alkyl})] \text{amino}$ , di(lower)alkylamino and phenylamino, or  $Y-Z$  is  $(CH_2)_{1-3}R^{10}$  wherein  $R^{10}$  is OH,  $(C_2-C_4)\text{acyloxy}$ ,  $SO_3H$ ,  $PO_4H_2$ ,  $N(NO)(OH)$ ,  $SO_2NH_2$ ,  $PO(OH)NH_2$ ,  $OCH_2CH_2N(CH_3)_3^+$ , or tetrazolyl or a pharmaceutically acceptable salt thereof. Lower alkyl, alkenyl, alkanoyl, etc. indicates a branched, cyclic or straight chain  $C_1-C_6$  group, preferably a  $C_1-C_4$  group, including cycloalkyl and (cycloalkyl)alkyl. (Hydroxy)lower alkyl or alkoxy is preferably 1- or 2-hydroxyethyl.

E2